Fibrillary GN Alert: Experts Redefine Treatment Non-Responders

In a recent clinical segment hosted by Hcplive, Dr. Andrew Bomback, MD, MPH, and Dr. Gerald Appel, MD, tackled a critical question in the management of fibrillary glomerulonephritis (FGN): how to define a non-responder to treatment. The discussion, aimed at practicing nephrologists, focused on practical parameters such as the degree of proteinuria reduction and the appropriate duration of therapy before concluding that a patient is not responding.

Fibrillary glomerulonephritis is a rare kidney disorder characterized by the deposition of fibrillary structures in the glomeruli, often leading to progressive kidney failure. While there is no standard therapy, immunosuppressive regimens are commonly used, but response rates vary. Drs. Bomback and Appel emphasized that defining non-response is not straightforward; it requires careful monitoring of proteinuria levels over time and consideration of individual patient factors. They noted that a lack of significant proteinuria reduction after a certain period—often 6 to 12 months—may indicate treatment failure, but the exact thresholds remain debated.

The insights from this expert dialogue highlight the need for standardized criteria to guide clinical decisions in FGN, a condition where evidence is limited. As research continues, such discussions are vital for helping clinicians optimize care and avoid unnecessary prolonged immunosuppression. The segment underscores the importance of personalized approaches and the ongoing quest for better biomarkers to predict treatment response.